Option Care Health (NASDAQ:OPCH) Shares Gap Up – Still a Buy?

Shares of Option Care Health, Inc. (NASDAQ:OPCH) gapped up before the market opened on Thursday . The stock had previously closed at $29.31, but opened at $30.43. Option Care Health shares last traded at $30.01, with a volume of 177,273 shares.

Analyst Ratings Changes

Several research firms recently commented on OPCH. JPMorgan Chase & Co. upped their target price on Option Care Health from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday. UBS Group assumed coverage on shares of Option Care Health in a research report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price on the stock. The Goldman Sachs Group lowered Option Care Health from a “buy” rating to a “neutral” rating and cut their target price for the stock from $38.00 to $27.00 in a research report on Monday, November 4th. Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and raised their target price for the company from $26.00 to $33.00 in a research note on Monday, January 13th. Finally, Barrington Research increased their price target on Option Care Health from $32.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.25.

Option Care Health Trading Up 1.1 %

The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. The firm has a market cap of $5.16 billion, a P/E ratio of 25.49, a price-to-earnings-growth ratio of 2.11 and a beta of 1.31. The business’s 50 day moving average is $24.42 and its 200-day moving average is $27.82.

Insider Transactions at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 43,000 shares of the business’s stock in a transaction on Friday, November 8th. The shares were purchased at an average price of $22.54 per share, with a total value of $969,220.00. Following the completion of the acquisition, the director now directly owns 326,334 shares of the company’s stock, valued at approximately $7,355,568.36. The trade was a 15.18 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.64% of the company’s stock.

Hedge Funds Weigh In On Option Care Health

Hedge funds and other institutional investors have recently modified their holdings of the company. UMB Bank n.a. grew its position in Option Care Health by 41.7% in the 4th quarter. UMB Bank n.a. now owns 1,176 shares of the company’s stock valued at $27,000 after buying an additional 346 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Option Care Health by 110.6% in the third quarter. GAMMA Investing LLC now owns 897 shares of the company’s stock valued at $28,000 after buying an additional 471 shares during the period. Lindenwold Advisors INC boosted its stake in Option Care Health by 5.4% during the third quarter. Lindenwold Advisors INC now owns 9,548 shares of the company’s stock valued at $299,000 after buying an additional 489 shares in the last quarter. Pacer Advisors Inc. grew its holdings in Option Care Health by 2.2% during the fourth quarter. Pacer Advisors Inc. now owns 25,483 shares of the company’s stock worth $591,000 after acquiring an additional 537 shares during the period. Finally, Sheets Smith Wealth Management raised its position in Option Care Health by 2.4% in the fourth quarter. Sheets Smith Wealth Management now owns 23,856 shares of the company’s stock worth $553,000 after acquiring an additional 550 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.